Remove 2026 Remove Clinical Research Remove Regulations
article thumbnail

Understanding the Impact of the New EU Artificial Intelligence Act on Clinical Research

Advarra

Artificial intelligence (AI) has taken the world by storm – and regulators are paying attention. The EU AI Act’s implications extend into clinical research, where AI is increasingly utilized for tasks like medical image analysis, natural language process for endpoint analysis, and generating/analyzing data for synthetic control arms.

article thumbnail

Article FDA Thank You The FDA rejected a psychedelic sponsor’s bid for approval. Here are six industry takeaways

Agency IQ

By Amanda Conti | Aug 13, 2024 10:00 PM CDT Regulatory context: Psychedelic regulation and drug development A growing body of evidence suggests that psychedelics may provide clinical benefit for certain purposes, especially mental health conditions. The study is planned to begin in 2026 and conclude in 2028.

FDA 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

From cradle to grave: Novo Nordisk Foundation and cardiometabolic diseases 

Drug Discovery World

million from the Foundation, which had committed itself for a five-year period (2021-2026), with the possibility of extending its support of the centre. When this was launched in September 2021, it was supported by a grant of up to $47.5

Disease 162
article thumbnail

Article FDA Thank You FDA updates set the stage for broader use of harmonized standards for safety reporting

Agency IQ

FDA updates set the stage for broader use of harmonized standards for safety reporting Though long considered a top priority by regulators, the process to standardize and harmonize the submission of individual case safety reports (ICSRs) has been slow. Periodic Benefit-Risk Evaluation Reports ).

FDA 40
article thumbnail

Sequana Medical to present at Jefferies 2020 Virtual London Healthcare Conference

The Pharma Data

and EU5 by 2026. The DSR therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. The DSR therapy is not currently approved for clinical research in the United States or Canada.

article thumbnail

Sequana Medical Announces January 2021 Investor Conference Schedule

The Pharma Data

and EU5 by 2026. The DSR therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. The DSR therapy is not currently approved for clinical research in the United States or Canada.

article thumbnail

Sequana Medical Appoints Two Additional Experts as Heart Failure Scientific Advisors

The Pharma Data

He is Director of Cardiovascular Research at the Duke Clinical Research Institute and Vice-Chief for Clinical Research in the Division of Cardiology. and EU5 by 2026. The DSR therapy is not currently approved for clinical research in the United States or Canada. Source link.